Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration

International Journal of Neuropsychopharmacology

Volumn 17, Issue 9, 2014, Pages 1367-1373

  Canestrelli, Corinne ^a,b,c   Marie, Nicolas ^a,b,c   Noble, Florence ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Buprenorphine; conditioned place preference; naloxone; suboxone

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; OPIATE RECEPTOR; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVERSIVE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; ANALYSIS OF VARIANCE; ANIMAL; AVOIDANCE BEHAVIOR; DRUG COMBINATION; DRUG EFFECTS; INSTRUMENTAL CONDITIONING;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BUPRENORPHINE; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; MALE; MICE; NALOXONE; NARCOTIC ANTAGONISTS; REWARD;

EID: 84904895642     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571400025X     Document Type: Article

References (35)

1. Alho H, Sinclair D, Vuori E, Holopainen A (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75-78.
2. Auriacombe M, Franques P, Tignol J (2001) Deaths attributable to methadone vs. buprenorphine in France. JAMA 285:45.
3. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 104:73-77.
4. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/ OFQ receptor. Peptides 21:1141-1146.
5. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH (2009) Pharmacokinetic interactions between buprenorphine/ naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 105:234-239.
6. Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD (2010) Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 105:709-718.
7. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D, Buprenorphine/Naloxone Collaborative Study G (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349:949-958.
8. Grisel JE, Mogil JS (2000) Effects of supraspinal orphanin FQ/nociceptin. Peptides 21:1037-1045.
9. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
10. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE (2007) Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction 102:1648-1656.
11. Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402.
12. Marquez P, Borse J, Nguyen AT, Hamid A, Lutfy K (2008) The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience 155:597-602.
13. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
14. Mattick RP, Kimber J, Breen C, Davoli M (2003a) Buprenorphine maintenance vs. placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207 Vol 2.
15. attick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C (2003b) Buprenorphine vs. methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98:441-452.
16. Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, Monier C, Noble F, Baud FJ (2006) Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 212:256-267.
17. Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW (2009) Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 28:226-231.
18. Murphy NP, Ly HT, Maidment NT (1996) Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 75:1-4.
19. Neeleman J, Farrell M (1997) Fatal methadone and heroin overdoses: time trends in England and Wales. J Epidemiol Community Health 51:435-437.
20. Ohtani M, Kotaki H, Sawada Y, Iga T (1995) Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510.
21. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Iwasawa Y, Ohta H (2000a) A potent and highly selective nonpeptidyl nociceptin/ orphanin FQ receptor (ORL1) antagonist: J-113397. Eur J Pharmacol 387:R17-R18.
22. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H (2000b) In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45-53.
23. Parfitt T (2006) Designer drug Subutex takes its toll in Tbilisi. Lancet 368:273-274.
24. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994) Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45:330-334.
25. Redrobe JP, Calo G, Regoli D, Quirion R (2002) Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol 365:164-167.
26. Rowlett JK, Gibson TR, Bardo MT (1994) Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats. Pharmacol Biochem Behav 49:241-245.
27. Sakoori K, Murphy NP (2004) Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl) 172:129-136.
28. Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC (2013) Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/mu-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther 346:11-22.
29. Sunjic S, Zador D (1997) Methadone-related deaths in New South Wales. Med J Aust 166:54-55.
30. Tzschentke TM (2004) Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology (Berl) 172:58-67.
31. Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12:227-462.
32. Villiger JW (1984) Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions. Neuropharmacology 23:373-375.
33. Wnendt S, Kruger T, Janocha E, Hildebrandt D, Englberger W (1999) Agonistic effect of buprenorphine in a nociceptin/ OFQ receptor-triggered reporter gene assay. Mol Pharmacol 56:334-338.
34. Yassen A, Olofsen E, Dahan A, Danhof M (2005) Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313:1136-1149.
35. Yassen A, Olofsen E, van Dorp E, Sarton E, Teppema L, Danhof M, Dahan A (2007) Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. Clin Pharmacokinet 46:965-980.